Update shared on30 Jul 2025
Fair value Increased 33%The significant upward revision in Thyrocare Technologies’ price target reflects higher consensus revenue growth forecasts, with fair value increasing from ₹1020 to ₹1355.
What's in the News
- Mr. Alok Kumar Jagnani has been elevated from CFO of Thyrocare Technologies to Group CFO of API Holdings Limited and is proposed to join Thyrocare's Board as a Non-Executive Director; he will step down as CFO.
- Mr. Vikram Gupta, a Chartered Accountant with over 20 years of experience in finance roles at companies like Rebel Foods, Tata Play Fiber, and Vodafone Idea, has been appointed as Thyrocare's new CFO and Key Managerial Personnel.
- The board scheduled a meeting to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025.
Valuation Changes
Summary of Valuation Changes for Thyrocare Technologies
- The Consensus Analyst Price Target has significantly risen from ₹1020 to ₹1355.
- The Consensus Revenue Growth forecasts for Thyrocare Technologies has significantly risen from 16.1% per annum to 19.3% per annum.
- The Future P/E for Thyrocare Technologies has risen from 34.98x to 38.41x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.